Sarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues
ABSTRACT In December 2024, the Society on Cachexia and Wasting Disorders (SCWD) hosted a Regulatory and Trial Update Workshop in Washington, D.C., bringing together experts from academia, industry, and the US Food and Drug Administration (FDA). This article summarizes key topics discussed during the...
Saved in:
Main Authors: | Stephan vonHaehling, Henning T. Langer, Steven B. Heymsfield, William J. Evans, Stefan D. Anker |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-06-01
|
Series: | Journal of Cachexia, Sarcopenia and Muscle |
Subjects: | |
Online Access: | https://doi.org/10.1002/jcsm.13841 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Endpoints: types, selection, interpretation of the results obtained on the example of cardiology studies
by: A. R. Navasardyan, et al.
Published: (2022-06-01) -
Expanding the use and interpretation of patient-centric cardiovascular clinical trial endpoints
by: Shelby D. Reed, et al.
Published: (2025-01-01) -
Selection of Endpoints for Clinical Studies of Ophthalmic Drugs
by: M. O. Komarova
Published: (2021-10-01) -
Is there a place for ultrasound in diagnosing sarcopenia?
by: Rondaij Tadej, et al.
Published: (2025-06-01) -
Nutrition and exercise for sarcopenia treatment
by: Hunkyung Kim, et al.
Published: (2025-06-01)